IN ATOPIC DERMATITIS, INFLAMMATORY CYTOKINES ARE AT THE HEART OF PERSISTENT,
UNDERLYING INFLAMMATION

ATOPIC DERMATITIS IS A CHRONIC, INFLAMMATORY SKIN DISEASE IN WHICH TH2 CYTOKINES ARE INVOLVED IN THE UNDERLYING INFLAMMATORY PROCESS1

Current evidence has shown that nonlesional skin is not normal skin, owing to persistent subclinical inflammation throughout the body.1-4 This underlying chronic inflammation is a source of the primary signs and symptoms of atopic dermatitis.1,3,4 Th2 dominance in tissue samples from patients with atopic dermatitis is well documented, with Th2-associated cytokines dominating the immune infiltrate.5

Studies of tissue samples from patients with atopic dermatitis have shown that acute and chronic lesions, as well as nonlesional skin, are associated with an increased:1,6-9

  • Number of immune cells that secrete inflammatory cytokines
  • Amount of Th2 signaling, compared with samples from healthy controls

Overview of the Th2 pathway involved in atopic dermatitis.

References: 1. Gittler JK, Shemer A, Suárez-Fariñas M, et al. Progressive activation of Th2/Th22 cytokines and selective epidermal proteins characterizes acute and chronic atopic dermatitis. J Allergy Clin Immunol. 2012;130(6):1344-1354. 2. De Benedetto A, Rafaels NM, McGirt LY, et al. Tight junction defects in patients with atopic dermatitis. J Allergy Clin Immunol. 2011;127(3):773-786. 3. Leung DYM, Boguniewicz M, Howell MD, Nomura I, Hamid QA. New insights into atopic dermatitis. J Clin Invest. 2004;113(5):651-657. 4. Suárez-Fariñas M, Tintle SJ, Shemer A, et al. Nonlesional atopic dermatitis skin is characterized by broad terminal differentiation defects and variable immune abnormalities. J Allergy Clin Immunol. 2011;127(4):954-964. 5. Guttman-Yassky E, Nograles KE, Krueger JG. Contrasting pathogenesis of atopic dermatitis and psoriasis─Part II: immune cell subsets and therapeutic concepts. J Allergy Clin Immunol. 2011;127(6):1420-1432. 6. Hamid Q, Boguniewicz M, Leung DYM. Differential in situ cytokine gene expression in acute versus chronic atopic dermatitis. J Clin Invest. 1994;94(2):870-876. 7. Lonati A, Licenziati S, Canaris AD, et al. Reduced production of both Th1 and Tc1 lymphocyte subsets in atopic dermatitis (AD). Clin Exp Immunol. 1999;115(1):1-5. 8. Tazawa T, Sugiura H, Sugiura Y, Uehara M. Relative importance of IL-4 and IL-13 in lesional skin of atopic dermatitis. Arch Dermatol Res. 2004;295(11):459-464. 9. Novak N, Bieber T, Leung DYM. Immune mechanisms leading to atopic dermatitis. J Allergy Clin Immunol. 2003;112(6 suppl):S128-S139. 10. Biedermann T, Skabytska Y, Kaesler S, Volz T. Regulation of T cell immunity in atopic dermatitis by microbes: the yin and yang of cutaneous inflammation. Front Immunol. 2015;6:353. doi:10.3389/fimmu.2015.00353. 11. Guttman-Yassky E, Dhingra N, Leung DYM. New era of biological therapeutics in atopic dermatitis. Expert Opin Biol Ther. 2013;13(4):549-561. 12. Noda S, Kruger JG, Guttman-Yassky E. The translational revolution and use of biologics in patients with inflammatory skin diseases. J Allergy Clin Immunol. 2015;135(2):324–36.